− The Genesis Exhibition: Do Ho Suh: Walk the House opens at Tate Modern in London in partnership with Genesis
− The exhibition presents three decades of Do Ho Suh's exploration on the themes of space, memory and identity, marking his first major solo exhibition in London in a generation
− Genesis Art Initiatives continues its collaboration with institutions and visionaries with an understanding of contemporary challenges and timeless values
SEOUL, South Korea, April 30, 2025 /PRNewswire/ -- Genesis and Tate Modern today announced the opening of The Genesis Exhibition: Do Ho Suh: Walk the House. On view from May 1 to October 19, 2025, the exhibition presents the breadth and depth of the artist Do Ho Suh's practice over the last three decades, celebrating the first major solo showing of his work in London in a generation.
As the first Genesis Art Initiatives program in Europe, The Genesis Exhibition: Do Ho Suh: Walk the House was made possible through the partnership between Genesis and Tate Modern, one of the leading institutes of modern and contemporary art. The expansive exhibition enables a deeper exploration of the artist's thought-provoking insight that resonates with the complexities of our time.
Do Ho Suh, a Seoul-born artist based in London, is known for examining the relationship between architecture, space, the body and the memories. Through his large-scale installations, sculptures, videos and drawings, the artist invites visitors to explore the themes of one's home, memory and identity, along with how we move through and inhabit the world around us.
The exhibition's title Walk the House is derived from "hanok," a traditional Korean house that could theoretically be disassembled, transported and reassembled at a new site, a process imagined as 'walking the house.' Reflecting this idea of a transportable home, the exhibition presents Suh's continuous practice that spans locations including Seoul, New York, and London — the three cities he has called home.
Visitors will be able to walk through his iconic fabric architectures — translucent 1:1 replicas of spaces in which the artist has lived and worked. These include the new site-specific installations Nest/s (2024) and Perfect Home: London, Horsham, New York, Berlin, Providence, Seoul (2024), presented alongside other newly created pieces on display for the first time.
The artist's reflections on both personal and collective memory expand on other major works like Rubbing/Loving: Seoul Home (2013-22) and Rubbing/Loving Project: Company Housing of Gwangju Theater (2012) — created through the labor-intensive process of rubbing the surfaces of buildings with graphite or colored pencil. Outside the entrance to the exhibition, visitors are also confronted with Who Am We? (2000), a wallpaper made up of tiny portrait photographs collected from sources including school yearbooks — an early example of the artist's exploration into the relationship between individual and group identity.
In addition, the exhibition includes the artist's intricate thread drawings and works on paper, as well as two video works — Robin Hood Gardens (2018) and Dong In Apartments (2022), considering the relationship between a building and a home.
The exhibition culminates in a space dedicated to Bridge Project — the artist's ongoing exploration of the notion of a 'perfect home' in collaboration with specialists in architecture, engineering, anthropology and biology.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Genesis and Tate Modern Announce the Opening of The Genesis Exhibition: Do Ho Suh: Walk the House
Genesis and Tate Modern Announce the Opening of The Genesis Exhibition: Do Ho Suh: Walk the House
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
